Scrip Asks... What Does 2026 Hold For Biopharma? Part 4: R&D Innovation
"Jacob Lalezari, CEO of CytoDyn, focused on immune activation strategies: “In 2026, oncology R&D wins will come from immune-first precision science grounded in real human biology, not the flashiest platforms. Programs with clear mechanistic links from immune regulation to tumor behavior will advance, powered by smarter patient selection, tighter biomarker strategies, and trials designed to reveal true signal. Momentum will center on tuning, not just accelerating the immune system. In parallel, strategies that ‘turn cold tumors hot,’ particularly in tough settings like triple-negative breast cancer, will increasingly make once-invisible tumors susceptible to meaningful immune attack.”
https://insights.citeline.com/scrip/scrip-ask...5CIZHE7OI/